Work

Hospital frailty risk score and one-year mortality after intravenous thrombolysis in older patients with acute ischemic stroke

Year: 2026
Type: article
Abstract: Background Frailty is a clinical syndrome characterized by a decline of function across multiple organ systems. It is also associated with higher short-term mortality following ischemic stroke. However, the impact of frailty on functional outcome in acute ischemic stroke remains uncertain. This study examines the association between frailty and one-year mortality after ischemic stroke in patients receiving intravenous thrombolysis. Methods In this monocentric retrospective cohort study, we calculated the Hospital Frailty Risk Score (HFRS) for all patients over 65 years with ischemic stroke who received intravenous thrombolysis from 2014 to 2019. Kaplan-Meier-Analysis and Cox-regression analysis were used to assess the impact of frailty on one-year mortality after ischemic stroke in these patients. Results A total of 423 patients were included in our analysis. Of these, 360 patients (85.2%) had a low risk of frailty (HFRS < 5) and 63 patients (14.9%) had an increased frailty risk with an HFRS ≥ 5. The NIHSS at discharge (3 [IQR 1–6] vs. 4 [ IQR 2–9] was higher in patients with frailty-risk. One-year mortality was 20.6% and 34.9%, respectively (log-rank p = 0.016). In multivariable Cox regression analysis adjusted for age, sex, Charlson Comorbidity Index, NIHSS at admission and ASPECTS, each one-point increase in the HFRS was associated with a higher hazard of one-year mortality (HR 1,085 (95% KI 1,015–1,160), p = 0,017). Adding the HFRS to the baseline clinical model improved model fit (likelihood ratio test, p = 0.028). Conclusions Among patients aged ≥ 65 years who received intravenous thrombolysis for acute ischemic stroke, a higher administratively derived HFRS was independently associated with a higher hazard of one-year mortality. These findings support further evaluation of the HFRS as a pragmatic prognostic marker but should not be interpreted as evidence for withholding reperfusion therapy. Clinical trial number not applicable.
Language: English
Field: Medicine
Open Access status: gold
Estimated APC paid: $3,090
OpenAlex ID: W7237338134
FWCI:
Cites: 24
Cited by:
Related to: